Policy | August 09, 2021
China NMPA approves phase II clinical trial of ASC40
Phase II trial will evaluate the safety and efficacy of ASC40 in patients with moderate to severe acne
Phase II trial will evaluate the safety and efficacy of ASC40 in patients with moderate to severe acne
Both companies aim to improve the efficiency and success rate of the current drug discovery process.
Filing for WHO Emergency Use Authorisation this month
Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells
Board declares interim dividend of Rs 2 per equity share
By 2022, 150,000 primary health care centres would be in place in rural as well as urban areas
The transaction is expected to close in the Q4FY22
Board approves fundraise of Rs 1500 crore
PAT rises to Rs 195.76 crore
Subscribe To Our Newsletter & Stay Updated
